MetaVia Inc. (NASDAQ:MTVA) Sees Significant Decrease in Short Interest

MetaVia Inc. (NASDAQ:MTVA) saw a significant decrease in short interest in December. As of December 31st, there was short interest totaling 19,683 shares, a decrease of 67.5% from the December 15th total of 60,602 shares. Based on an average daily volume of 34,079 shares, the short-interest ratio is presently 0.6 days. Approximately 0.9% of the shares of the stock are sold short. Approximately 0.9% of the shares of the stock are sold short. Based on an average daily volume of 34,079 shares, the short-interest ratio is presently 0.6 days.

Hedge Funds Weigh In On MetaVia

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC grew its stake in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 60,386 shares of the company’s stock after buying an additional 18,506 shares during the period. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 as of its most recent SEC filing. 1.37% of the stock is owned by institutional investors.

MetaVia Stock Down 39.1%

Shares of MTVA stock traded down $2.12 during mid-day trading on Thursday, hitting $3.30. 1,786,902 shares of the company’s stock were exchanged, compared to its average volume of 235,260. The stock has a market cap of $7.26 million, a price-to-earnings ratio of -0.39 and a beta of 0.27. MetaVia has a fifty-two week low of $3.00 and a fifty-two week high of $23.54. The stock has a 50-day simple moving average of $8.45 and a two-hundred day simple moving average of $8.74.

MetaVia (NASDAQ:MTVA) last released its earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($2.86) by $1.32. As a group, analysts anticipate that MetaVia will post -3.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on MTVA shares. HC Wainwright lifted their price objective on MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Finally, Wall Street Zen upgraded MetaVia to a “sell” rating in a research report on Saturday, January 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $36.50.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.